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 Implication for health policy/practice/research/medical education:
This article presents that IDUs are highly at risk of hepatitis B and C virus infections. This has an important implication for those 
who are involved in planning for providing harm reduction services, especially in prison settings.
Background: In Iran, the number of injecting drug users (IDUs) has increased in recent 
years. The rates of hepatitis C virus (HCV) and hepatitis B virus (HBV) infections among 
IDUs are reportedly high.  
Objectives: The purpose of this study was to assess factors correlated with HCV and HBV 
infections among IDUs in Tehran. 
Patients and Methods: A cross-sectional study included 899 IDUs recruited from the com-
munity, drug treatment centers, and drop-in-centers. The study involved interviews con-
ducted using an adapted version of the WHO Drug Injection Study Phase II (Version 2b) 
questionnaire and blood testing for the HCV antibody, hepatitis B surface antigen, and 
hepatitis B core antibody. A logistic regression model was used to identify independent 
factors correlated with HCV and HBV infections. 
Results: HCV infection was found to be primarily associated with female gender [odds 
ratio (OR) 5.0, 95% confidence interval (CI) 2.0–10.0)], unmarried status (OR 2.9, 95% CI 
1.9–4.4), drug use for more than 10 years (OR 2.7, 95% CI 1.8–3.9), drug injection frequency 
of more than once per day (OR 2.6, 95% CI 1.6–4.2), history of imprisonment (OR 2.5, 95% 
CI 1.6–4.0)], and a history of shared injection needles in prison (OR 2.3, 95% CI 1.5–3.6). HBV 
infection was mainly correlated with a history of imprisonment (OR 1.9, 95% CI 1.4–2.7) 
and drug use for more than 10 years (OR 1.4, 95% CI 1.1–1.9). 
Conclusions: Because a considerable number of IDUs in Iran are receiving reduction ser-
vices, tailoring services for prevention of hepatitis infection are necessary.
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1. Background
For decades, Iran was facing a high rate of opium use, 
as a producer country. Thirty years after total eradication 
of opium poppy cultivation, Iran is experiencing a rapid 
shift towards more severe patterns of drug use. In 1999, 
it was estimated that 166,000 injecting drug users (IDUs) 
live in Iran (1). Currently, it is estimated that there are 
more than 260,000 IDUs in the country (2). To address 24 Correlates of HCV & HBV Infections in IDUs Amin-Esmaeili M et al.
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this sharp increase in injection drug use and its health-
related  consequences,  harm-reduction  initiatives  were 
started in 2002 and have expanded since 2005. Hepati-
tis C virus (HCV) is a major cause of chronic liver disease 
worldwide and a potential contributor to morbidity and 
mortality (3). In Iran, the prevalence of HCV infection 
in the general population has been estimated to be less 
than 1% (4); this is significantly less than the estimated 
prevalence in the world population (3%) (5). Since ini-
tiation of routine screening for HCV in donated blood, 
transfusions have virtually been eliminated as a source of 
HCV transmission. Therefore, most newly acquired cases 
of hepatitis C are related to injecting drug use, mainly 
due to unsafe injection practices (6-8). The prevalence of 
hepatitis B virus (HBV) infection in the general popula-
tion of Iran ranges from 1.7% to 5% (9), which is in an in-
termediate range of endemicity (10). In a review, Custer 
et al. found that the prevalence of chronic HBV infection 
in the general population was highly variable, ranging 
from greater than 10% in some Asian and Western Pacific 
countries to less than 0.5% in the United States and north-
ern European countries (11). Additionally, injecting drug 
use was identified as a risk factor for hepatitis B in many 
countries (11).
2. Objectives
High rates of HCV and HBV infections among IDUs have 
been reported in Iran (12-14). Few studies have evaluated 
the risk factors related to these rates. This study is a part 
of a larger study examining the characteristics, risk be-
haviors, and risk factors of hepatitis C, hepatitis B, and 
human immunodeficiency virus (HIV) infections among 
IDUs in Tehran, the capital city of Iran. This paper pres-
ents the results related to the prevalence of HCV and HBV 
infections and the correlating factors in this population. 
3. Patients and Methods
3.1. Population and Field Work
This cross-sectional study was conducted between June 
2006 and March 2007 and involved 904 current IDUs se-
lected from drug treatment centers and the community. 
Drug users were included in the study if they had a histo-
ry of injecting drug use over the 2-month period prior to 
the study and consented to participate in the interviews. 
Using purposive sampling with ethnographic observa-
tions in public places, peer referrals, and assessments 
of snowballing effects, a community sample population 
was selected from five areas of Tehran with high rates of 
drug use. Another sample population was selected from 
three  drug-treatment  centers  and  two  drop-in-centers 
(DICs) located in different, well-known areas of Tehran 
with high rates of drug use. Treatment centers provide 
methadone  maintenance  treatment  (MMT),  and  DICs 
mainly provide other types of harm-reduction interven-
tions, including needle and syringe programs (NSP) and 
harm-reduction education. Cases were selected based on 
consecutive admissions to the centers during the study 
time  period.  We  used  the  questionnaire  of  the  “WHO 
Drug Injection Study Phase II (Version 2b)” for data col-
lection. Three psychiatrists adapted the questionnaire 
according to the situation in Iran, which was followed by 
a pretest assessment on a sample of IDUs. The question-
naire included assessments of socio-demographic char-
acteristics, drug use and injecting drug use practices, 
sexual  risk  behaviors,  knowledge  regarding  hepatitis 
infection, and service use. 
Fieldwork, including interviews and blood sampling, 
was carried out by experienced drug therapists and out-
reach workers after a short training course that included 
questionnaire training and instructions on transferring 
blood samples to the laboratory. There was no monetary 
incentive for participation in this study. However, the use 
of free-of-charge health services, including drug treat-
ment, was offered as an incentive. 
3.2. Blood Sample
Blood samples were tested for the HCV antibody (anti-
HCV ELISA, DRG Co., Germany), hepatitis B surface anti-
gen  (HBsAg  IEMA  WELL,  Radim,  Italy),  and  hepatitis  B 
core antibody (anti-HBc EIA WELL, Radim, Italy). A posi-
tive result either for HBsAg or anti-HBc was considered 
to indicate “past or current HBV infection.” All positive 
and borderline-positive samples for HBsAg, anti-HBc, 
and anti-HCV were retested using the same method. We 
excluded  samples  that  repeatedly  showed  borderline-
positive results. All tests were conducted at the Keyvan 
Laboratory. 
3.3. Statistical Analysis
Statistical  analyses  were  performed  using  SPSS  for 
Windows (version 16.0, 2007; SPSS Inc., Chicago, IL, USA). 
Univariate analysis was conducted using chi-square test 
for binomial variables. All variables were included in the 
multivariable analysis. A multivariate logistic regression 
model using a forward conditional method was used to 
identify independent correlates of HCV and HBV infec-
tions. Associations were assessed using the odds ratios 
and 95% confidence intervals, and adjusted odds ratios 
were determined through multivariate analysis. 
3.4. Ethical Considerations
The research protocol was approved by the ethics com-
mittee of Tehran University of Medical Sciences in Iran. 
Participation in the study was on a voluntary basis, and 
informed consent was obtained for the interview as well 
as for collecting blood samples. All efforts were made to 
guarantee privacy and confidentiality during the inter-
views. A de-linked method for testing was carried out 
to ensure confidentiality of the results. An identifica-
tion code, which was used for laboratory results as well, 
was included on each questionnaire. Participants were 
ensured that non-participation in the study would not 
affect their treatment or harm-reduction service utiliza-
tion. 25 Correlates of HCV & HBV Infections in IDUs Amin-Esmaeili M et al.
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4. Results 
A total of 904 IDUs were enrolled in the study. Most 
of the participants (95.8%) were male. Participant ages 
ranged from 16 to 65 years, with a mean age [standard 
deviation (SD)] of 33.9 (9.4) years. The mean (SD) years of 
education was 7.7 (3.5) years. Most subjects were unmar-
ried (70.8%) and unemployed (64.1%). Socio-demographic 
profiles of participants recruited from drug treatment 
centers, DICs, and the community are presented in Table 
1. The mean (SD) age at first drug use was 19.7 (4.0) years. 
The main injected drug used within the last 6 months 
was heroin (81.3%), and the mean (SD) duration of drug 
injection  was  8.4  (7.6)  years.  Most  participants  (76.6%) 
reported  injecting  with  used  injection  equipment,  in-
cluding needles and syringes, or sharing other injection 
paraphernalia  within  the  last  six  months.  Among  the 
participants, 70.9% had a history of imprisonment, and 
21.5% of these had a history of sharing injection equip-
ment in prison. 
With  regard  to  sexual  behavior,  36.4%  of  the  partici-
pants reported an extramarital relationship (either het-
erosexual or homosexual) within the last 6 months, and 
of these, 80% had a history of intercourse without protec-
tion during the same period. An extramarital relation-
ship without protection was defined as “high-risk sexual 
behavior.” Five of the interviewees refused to participate 
in blood testing. In the HCV antibody testing, four sam-
ples showed repeated borderline results. Of the remain-
ing 895 participants, 34.5% (CI 31.4–37.7%) tested positive 
for  HCV.  In  univariate  analysis,  several  variables  were 
identified as factors correlated with transmission of hep-
atitis C among the participants. Recruitment from DICs 
and the community, older age, unmarried status, home-
lessness and living alone, history of imprisonment and 
unsafe sharing practices in prison, initiation of drug use 
at a young age, longer duration of drug use and duration 
of injecting drug use, more frequent injecting drug use, 
history of overdose, and recent use of harm-reduction 
services were associated with a higher prevalence of HCV 
infection (Table 2). 
Multivariate logistic regression analysis revealed that 
the following independent factors were associated with 
HCV infection: recruitment from DICs and the commu-
nity, female gender, unmarried status, longer duration of 
drug use, injection frequency of more than once per day, 
history of imprisonment and history of shared injection 
in prison, and use of a harm-reduction service during the 
past six months. The analysis also showed that sharing 
injection paraphernalia during the past six months was 
reversely associated with HCV infection (Table 2). Further 
analysis showed that among participants who had used 
harm-reduction services in the past six months, the rate 
of recent sharing behavior was less than those who had 
not used the services (73.2% vs. 79.9%, P < 0.02). HBV test-
ing showed borderline results or insufficient samples in 
35 (3.5%) cases, which were excluded from the analysis. 
Of the 864 remaining subjects, 40 cases showing a weak 
positive result for HBsAg and negative results for anti-
HBc were regarded as negative cases. HbsAg was detect-
ed in 24.7% and anti-HBc in 29.1% of the 864 cases. Overall, 
46.1% of cases showed either past or current HBV infec-
tion. Univariate analysis revealed older age, history of 
imprisonment, longer duration and more frequent drug 
use, history of drug overdose, and recent drug-treatment 
service use as risk factors for HBV infection among IDUs. 
Multivariate logistic regression analysis showed that his-
tory of imprisonment and a longer duration of drug use 
were independently correlated with HBV infection (Table 
2). 
5. Discussion 
In  this  study,  we  investigated  the  factors  correlated 
with the transmission of HCV and HBV among IDUs in 
Tehran, the capital city of Iran. This is the largest study 
evaluating HCV and HBV infections and their correlated 
factors among IDUs in Iran. Only one study, which was 
conducted in 2004, has assessed the factors correlated 
with HCV infection among 202 non-incarcerated male 
IDUs in Tehran (13). 
5.1. Prevalence of Hepatitis C in IDUs
We found that the prevalence of HCV was 34.5% in the 
sample IDU population. Among studies with a minimum 
sample size of 100, there have been three studies examin-
Drug Treatment Center (n = 158) DICs a (n = 290) Community (n = 446)
Gender
Female
Male
1
20
1
20
1
25
Age, y, mean ± SD 34.2 ± 9.4 34.2 ± 9.8 33.5 ± 9.2
Full-time education, y, mean ± SD 8.0 ± 3.7 8.2 ± 3.3 7.3 ± 3.5
Single; widowed; or separated, % 47.8 71.2 78.7
Homeless, % 5.8 30.1 56.4
Living alone, % 14.5 34.7 56.2
Unemployed, %  26.9 67.2 75.6
History of imprisonment, % 38.6 75.9 78.8
 Table 1. Socio-Demographic Profile of the Study Sample in Three Different Settings
a Abbreviation: DICs, drop-in centers26 Correlates of HCV & HBV Infections in IDUs Amin-Esmaeili M et al.
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ing non-incarcerated IDUs in Iran; in these studies, the 
prevalence of HCV infections was 11.2% (12), 30.5% (14), and 
52% (13). Among incarcerated IDUs, reported HCV preva-
lence rates are higher, ranging from 31.5% to 81.8% (14-18). 
HCV prevalence among non-incarcerated IDUs has also 
been reported in neighboring countries. In Afghanistan, 
the prevalence of HCV is reportedly 36.6% in the capital 
city of Kabul (19); Pakistan reported higher rates, rang-
ing from 88% to 94.3% (20-22). In a recent report, the HCV 
prevalence among IDUs in South and Southeast Asia 
ranged from 10 to 100% (23). Our study showed a medium 
HCV prevalence rate among non-incarcerated IDUs. 
5.2. Variables Correlated With Hepatitis C
Our findings indicate that HCV infection is associated 
with  female  gender,  a  history  of  imprisonment  and 
shared injection in prison, drug injection frequency 
of more than once per day, drug use for more than 10 
years, and unmarried status. A key finding of this study 
is the association between gender and the risk of hepa-
titis C transmission. A similar finding has been reported 
in England, in which female gender was identified as a 
risk factor for HCV infection (24). Other studies have not 
identified such a relationship (25, 26). Several social and 
demographic factors may predispose female drug users 
to acquiring blood-borne infections. A lack of gender-
specific services in communities, stigma, financial de-
pendence on a partner, and partner pressure (27, 28) have 
been identified in other studies in Iran as limiting factors 
for female drug users’ access to and utilization of treat-
ment and prevention resources. Involvement in high-
risk behaviors such as sex-for-money and sex-for-drugs 
have been reported as well. Similar to our study, other 
studies have reported imprisonment as a major risk fac-
tor for hepatitis C transmission in Iran and around the 
world. In Iran, the duration of incarceration (> 1 year) 
was previously identified as a risk factor (13). These find-
ings are consistent with studies conducted in Western 
countries that identified history of imprisonment, in-
cluding duration and/or number of incarcerations, as 
factors associated with HCV seroconversion (29-31). Our 
study indicated that approximately 70% of participants 
had a history of imprisonment, of which more than one-
fifth shared needles while in prison. Since 2005, harm-
reduction interventions inside Iranian prisons have 
been expanded; however, only one qualitative study has 
reported a significant decrease in injection drug use in 
one prison (32). 
We found that drug injection frequency of more than 
once per day and drug use duration of more than 10 
years were associated with high rates of HCV infection. 
Duration of injection drug use (> 10 years) has been re-
ported as a risk factor in another study in Iran (13). These 
findings are consistent with the results reported in other 
countries (22, 25, 29, 33, 34). However, we found an HCV 
seroprevalence of 18.2% among IDUs who had been inject-
ing drugs for less than two years. This finding indicates a 
more rapid rate of infection and suggests that infection 
occurs shortly after the initiation of injection practices. 
Other reports have also reported a rapid increase in HCV 
infection upon initiation of drug injection (35-38). The 
high prevalence of hepatitis C infection among IDUs par-
ticipating in high-risk behaviors such as needle sharing 
make unsafe injection the primary cause of hepatitis C 
transmission in developed countries (5, 34). Studies con-
ducted in countries in this region, such as Pakistan (39) 
and Georgia (40), have reported unsafe injection to be 
the main cause of hepatitis C transmission among their 
populations.  However,  a  meta-analysis  of  the  factors 
correlated with HCV in China showed no significant dif-
ference  between  needle-sharing  IDUs  and  non-needle-
sharing IDUs (25). In our study, sharing behavior during 
the last six months was reversely associated with HCV in-
fection. This result, along with the finding of no relation-
ship between HCV infection and knowledge of hepatitis 
C infection, suggests that the knowledge and behavior of 
IDUs with a long history of drug use and injecting drug 
use have improved. This also correlates with the finding 
that HCV infection is more prevalent among IDUs who 
used harm-reduction services during the last six months 
than among those who had not used the services. 
In this study, no association was identified between re-
cent high-risk sexual behavior and hepatitis C infection. 
Other studies also found HCV infection to be unrelated to 
sexual practices (26, 33, 35, 40, 41), confirming that hep-
atitis C among IDUs appears to be a consequence of re-
peated exposure to contaminated injection equipment.
5.3. Prevalence of Hepatitis B Among IDUs
The prevalence of past or current HBV infection was 
46.1% in the study population. In another study exam-
ining incarcerated IDUs in Tehran, HBcAb was detected 
in 61.2% of the participants (42). Among studies with a 
minimum sample size of 100, only one study examin-
ing non-incarcerated IDUs was conducted in Iran, which 
reported a positive HBsAg result in 6% of the cases (12). 
The reported rates of IDUs in Kabul (6.5%) (19) and Kara-
chi (7.5%) (20) are also relatively low. Injecting drug use 
is reportedly the primary risk behavior in new cases of 
hepatitis B in males in Egypt (43). There are also reports 
of a greater than 50% rate of HBV infection among IDUs 
in other countries (40, 44, 45). However, the high rate 
of  HBV  infection  found  in  our  study  requires  further 
investigation. Notably, in Iran, a national program for 
hepatitis B vaccination in newborns was begun in 1992; 
however, no specific vaccination plan for drug users has 
been established.
5.4. Variables Correlated With Hepatitis B
This is the second study that has explored factors cor-
related with HBV infection among IDUs in Iran. In our 
study, HBV infection was mainly correlated with a history 
of imprisonment and drug use for more than 10 years. 
These results are consistent with a report from Iran (46) 29 Correlates of HCV & HBV Infections in IDUs Amin-Esmaeili M et al.
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and reports from other countries regarding risk factors 
of HBV infection in IDUs that have identified imprison-
ment (45, 47) and the frequency (48) and duration of 
drug injection (45, 49) as risk factors of HBV infection.
5.5. Limitations of the Study
Drug use is often a hidden behavior, and drug users are 
considered a hard-to-reach population. Therefore, select-
ing a representative sample of drug users in a geographi-
cal  area  is  difficult.  However,  methods  that  are  more 
representative are recommended, such as respondent-
driven sampling or a hybrid sampling plan using several 
methods (50, 51), as was used in our study. Additionally, 
sampling was conducted such that a higher number of 
IDUs in Tehran were involved in the study, and the results 
may not be generalized to the entire Iranian IDU popula-
tion. Another limitation is that study participants were 
interviewed regarding their past circumstances and re-
call bias may be an issue. Additionally, respondents may 
have been under influence of drugs at the time of inter-
view and may not have provided precise data. This study 
had a cross-sectional design, and the temporal relation-
ship between correlated factors and HCV and HBV sero-
positivity cannot be proven. 
Blood-borne infections pose a serious threat to the 
health of injecting drug users. Factors related to hepati-
tis B and C virus infections appear to be similar among 
IDUs. The findings explain the reasons behind the high 
rate of co-infections found in our study and explained 
elsewhere (52). Since 2005, there have been continuous 
efforts to increase coverage of harm-reduction interven-
tions in Iran. The intermediate prevalence of hepatitis 
C infection and the high rate of hepatitis B infection 
observed in our study highlight the importance of ad-
ditional studies on the long-term effectiveness of harm-
reduction interventions. Reports from other countries 
have also demonstrated that HIV preventive measures 
for IDUs are not always effective in controlling viral hep-
atitis (53). Additionally, prison is a known predisposing 
environment for HIV transmission in Iran. Our study re-
vealed the importance of prisons in acquiring HCV and 
HBV infection, as well. However, as a considerable num-
ber of IDUs in Iran are covered under harm-reduction 
programs, either in the community or in prison (54), 
these results present a good opportunity to tailor servic-
es for hepatitis patients to decrease exposure to contami-
nated blood as well as risk reduction in sexual behaviors. 
We also suggest primary prevention of initiating injec-
tion drug use in addition to a provision for hepatitis B 
vaccination and HCV and HBV infection testing for IDUs.
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